Journal of cancer research and clinical oncology · 2025
Comparison of 68Ga-FAPI-04 PET/CT with CECT in the evaluation of peritoneal metastases from gastrointestinal cancers and impact on clinical decision-making.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Yushan, Zhao Yaqin, Shuai Dandan, Yang Xibiao, Hu Qiancheng, Deng Xiangbing, Li Qianrui, Su Minggang
Аннотация
PURPOSE: To investigate the diagnostic accuracy of 68Ga-FAPI-04 PET/CT for peritoneal metastasis in gastrointestinal cancers and to assess its impact on clinical decision-making, comparing to contrast-enhanced computed tomography (CECT).
METHODS: We retrospectively included consecutive patients with gastrointestinal cancers, admitted between April 2022 and October 2022, and underwent both 68Ga-FAPI-04 PET/CT and CECT within two weeks. The reference standard was histopathology or imaging follow-up. We compared patient-level accuracy to detect peritoneal metastases and to measure peritoneal tumor burden between 68Ga-FAPI-04 PET/CT and CECT. We assessed the impact of 68Ga-FAPI-04 PET/CT on treatment through a simulated multidisciplinary tumor board.
RESULTS: We included 57 patients, among which, 34 (59.65%) had peritoneal metastasis. 68Ga-FAPI-04 PET/CT showed superior sensitivity (97.06% vs. 64.71%) and specificity (95.65% vs. 78.26%) than CECT, as well as area under the curve (0.964 vs. 0.715, P < 0.001). Among patients with peritoneal metastasis, 68Ga-FAPI-04 PET/CT revealed higher peritoneal tumor burden than CECT (peritoneal cancer index [PCI]-region: 6.5 vs. 1, P < 0.001). 68Ga-FAPI-04 PET/CT findings led to changes of treatment in 17 (29.82%) patients, among which, nine (15.8%) patients had new findings related to peritoneum. The impact was deemed high in 10 (17.54%) patients, moderate in six (10.53%), and low in one (1.75%).
CONCLUSIONS: 68Ga-FAPI-04 PET/CT has the potential to influence clinical decision-making in gastrointestinal cancers and has superior accuracy than CECT. Further studies are warranted to support routine use.
METHODS: We retrospectively included consecutive patients with gastrointestinal cancers, admitted between April 2022 and October 2022, and underwent both 68Ga-FAPI-04 PET/CT and CECT within two weeks. The reference standard was histopathology or imaging follow-up. We compared patient-level accuracy to detect peritoneal metastases and to measure peritoneal tumor burden between 68Ga-FAPI-04 PET/CT and CECT. We assessed the impact of 68Ga-FAPI-04 PET/CT on treatment through a simulated multidisciplinary tumor board.
RESULTS: We included 57 patients, among which, 34 (59.65%) had peritoneal metastasis. 68Ga-FAPI-04 PET/CT showed superior sensitivity (97.06% vs. 64.71%) and specificity (95.65% vs. 78.26%) than CECT, as well as area under the curve (0.964 vs. 0.715, P < 0.001). Among patients with peritoneal metastasis, 68Ga-FAPI-04 PET/CT revealed higher peritoneal tumor burden than CECT (peritoneal cancer index [PCI]-region: 6.5 vs. 1, P < 0.001). 68Ga-FAPI-04 PET/CT findings led to changes of treatment in 17 (29.82%) patients, among which, nine (15.8%) patients had new findings related to peritoneum. The impact was deemed high in 10 (17.54%) patients, moderate in six (10.53%), and low in one (1.75%).
CONCLUSIONS: 68Ga-FAPI-04 PET/CT has the potential to influence clinical decision-making in gastrointestinal cancers and has superior accuracy than CECT. Further studies are warranted to support routine use.